Trial reportTrials2021
Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial.
Trial report in Trials, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04443062 (Lutetium-177-PSMA-617 Radioligand Therapy in Oligo-metastatic Hormone Sensitive Prostate Cancer.), which is not on this map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Lutetium-177-PSMA-617 Radioligand Therapy in Oligo-metastatic Hormone Sensitive Prostate Cancer.
Who cites it
20 citing papers in PubMed, 29 citations in OpenAlex.
- 177 Lu-PSMA for prostate cancer: progress, challenges and future perspectives.Asian journal of andrology · 2026Review
- Impact of PSMA-Based Radiopharmaceuticals on the Clinical Management of Prostate Cancer.Cancers · 2026Article
- Association of Prior PARP Inhibitor Exposure with Clinical Outcomes afterEuropean urology oncology · 2026Article
- Theranostics 2.0: Target-driven, artificial intelligence-enabled cancer therapy across tumor types.Diagnostic and interventional imaging · 2025Review
- Optimization of the radiosynthesis of the PSMA-targeting drugs [EJNMMI radiopharmacy and chemistry · 2025Article
- [PSMA radioligand therapy-State of the art].Urologie (Heidelberg, Germany) · 2025Review
- The role of PSMA-based radioligand therapy in hormone-sensitive prostate cancer.European journal of nuclear medicine and molecular imaging · 2025Review
- Role of Lutetium Radioligand Therapy in Prostate Cancer.Cancers · 2024Review
- Assessment of PSMA Expression of Healthy Organs in Different Stages of Prostate Cancer Using [Cancers · 2024Article
- Oligometastatic Prostate Cancer-The Middle Child Syndrome.Journal of clinical medicine · 2023Review
- New perspectives on metabolic imaging in the management of prostate cancer in 2022: A focus on radiolabeled PSMA‑PET/CT (Review).Molecular and clinical oncology · 2023Review
- Article
- PSMA-Targeted Radiopharmaceuticals in Prostate Cancer: Current Data and New Trials.The oncologist · 2023Article
- Review
- Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials.Therapeutic advances in medical oncology · 2023Review
- Novel radionuclide therapy combinations in prostate cancer.Therapeutic advances in medical oncology · 2023Review
- PSMA-RLT in Patients with Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective Study.Cancers · 2022Article
- Current Status of PSMA-Targeted Radioligand Therapy in the Era of Radiopharmaceutical Therapy Acquiring Marketing Authorization.Nuclear medicine and molecular imaging · 2022Review
- Oligometastatic Prostate Cancer: Current Status and Future Challenges.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Review
- Recent Advances in the Management of Hormone-Sensitive Oligometastatic Prostate Cancer.Cancer management and research · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe BULLSEYE trial is a multicenter, open-label, randomized controlled trial to test the hypothesis if CHANGES IN METHODS AND MATERIALS: Two important changes were made to the original protocol: (1) the study will now use
conclusionsWe present an update of the original study protocol prior to the completion of the study. Treatment arm patients that were included and received
trial registrationClinicalTrials.gov NCT04443062 . First posted: June 23, 2020.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.